Lewy body dementia

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on:

Wednesday, August 4, 2021

Medical specialties, Branches of biology, Clinical medicine, Vaccination, Alpha-synuclein, Lewy body dementia, Vaccine, Parkinson's disease

LAUSANNE, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended June 30, 2021, and provided a corporate update.

Key Points:

Announced an all-stock acquisition of Affiris portfolio of therapeutics targeting alpha-synuclein notably PD01, a clinically validated active vaccine candidate that places AC Immune at the forefront of Parkinsons disease drug development.
The study is currently under analysis and AC Immune plans to present the results at an international Alzheimer conference.
SupraAntigen is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU.
Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.

Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB

Retrieved on:

Monday, May 17, 2021

Biotechnology, Pharmaceutical, Health, Other Health, Branches of biology, Peripheral membrane proteins, Neurological disorders, Alpha-synuclein, Lewy body dementia, Synuclein, Neurodegeneration, UCB

b'Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson\xe2\x80\x99s Disease.

Key Points:

b'Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson\xe2\x80\x99s Disease.
UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies, Inc and UCB Biopharma SRL on December 31, 2014.
We believe that inhibition of alpha-synuclein misfolding and oligomerization with an orally active, brain penetrating, small molecule represents a promising therapeutic approach.
As a result of this latest milestone achievement, Neuropore Therapies has cumulatively received $63 million (USD) of the potential $460 million (USD) in total milestones available through its collaboration with UCB.\nParkinson\xe2\x80\x99s disease (PD) is the second most common neurodegenerative disorder after Alzheimer\xe2\x80\x99s disease.

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease

Retrieved on:

Monday, May 10, 2021

Branches of biology, Peripheral membrane proteins, Health, Clinical research, Design of experiments, Lewy body dementia, Alpha-synuclein, Neuropathology, Clinical trial, Parkinson's disease, Synuclein, Placebo-controlled study

PADOVA is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of prasinezumab in patients with early Parkinson\xe2\x80\x99s disease who are on stable symptomatic medication.

Key Points:

PADOVA is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of prasinezumab in patients with early Parkinson\xe2\x80\x99s disease who are on stable symptomatic medication.
The study will enroll approximately 575 patients, who will be randomized to receive either prasinezumab or placebo via intravenous infusion every 4 weeks.
Prasinezumab is designed to block the cell-to-cell transmission of the aggregated, pathogenic forms of alpha-synuclein in Parkinson's disease, thereby slowing clinical decline.
Prior to initiating clinical trials, the efficacy of prasinezumab was evaluated in various cellular and animal models of alpha-synuclein-related disease.

2021 Global Lewy Body Dementia Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Retrieved on:

Friday, May 7, 2021

Pharmaceutical, Health, Mental health, Lewy body dementia, Cognitive disorders, Psychiatric diagnosis, Branches of biology, Psychiatry, Learning disabilities, Abnormal psychology, Aging-associated diseases, Dementia, Lewy body, Lewy, Dementia with Lewy Bodies Consortium

b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.

Key Points:

b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.
The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Lewy Body Dementia patients, history of the disease at the population level (Lewy Body Dementia prevalence, Lewy Body Dementia incidence) and at the clinical level (from diagnosis to treated patients).
It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nLewy Body Dementia patient flow: Lewy Body Dementia prevalence, diagnosed, and drug-treated patients\nDemographics: Lewy Body Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Lewy Body Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Lewy Body Dementia patients segments through age groups, gender, and disease sub-types\nEvaluate Lewy Body Dementia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005374/en/\n'

ATH434 protects brain cells and improves motor function in Parkinsonian disorder

Retrieved on:

Wednesday, April 21, 2021

Neurological disorders, Branches of biology, Organ systems, Neurodegenerative disorders, Lewy body dementia, Parkinson's disease, Multiple system atrophy, Dopamine, Alpha-synuclein, Animal models of Parkinson's disease

The presentation titled ATH434 Preserves Dopaminergic Neurons, Reduces -synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model [1] will be delivered on 21st April.\nThe data to be presented further strengthens the evidence that ATH434 is neuroprotective in brain regions implicated in Parkinsonian disorders.

Key Points:

The presentation titled ATH434 Preserves Dopaminergic Neurons, Reduces -synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model [1] will be delivered on 21st April.\nThe data to be presented further strengthens the evidence that ATH434 is neuroprotective in brain regions implicated in Parkinsonian disorders.
The data, from an animal model of Multiple System Atrophy (MSA), independently confirm and extend previous findings demonstrating that ATH434 reduces -synuclein pathology, preserves neurons, and improves motor function.
Impaired motor performanceis a cardinal symptom of Parkinsonian disorders.\nThe improvement in motor performance associated with ATH434 was shown on a task that is specifically designed to assess coordination and balance in animals.
ATH434 has been shown to reduce abnormal accumulation of -synuclein and tau proteins in animal models of disease by redistributing labile iron in the brain.

SciNeuro Pharmaceuticals Announces Exclusive Licensing Agreement with Eli Lilly & Company

Retrieved on:

Wednesday, April 14, 2021

Biotechnology, Pharmaceutical, Health, Clinical trials, Life sciences, Peripheral membrane proteins, Health sciences, Branches of biology, Alpha-synuclein, Lewy body dementia, Eli Lilly and Company, Biopharmaceutical, Synuclein, Pharmaceutical industry in China, Eli Lilly and Company, SciNeuro Pharmaceuticals

b'SciNeuro Pharmaceuticals , an innovative biopharmaceutical company focused on delivering transformative therapies to patients with neurological diseases, has entered into an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.\nUnder the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.

Key Points:

b'SciNeuro Pharmaceuticals , an innovative biopharmaceutical company focused on delivering transformative therapies to patients with neurological diseases, has entered into an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.\nUnder the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.
Lilly will receive an upfront cash payment, in addition to downstream milestones and royalties on products developed and commercialized by SciNeuro.
Lilly retains all rights outside Greater China.\n\xe2\x80\x9cApproximately 3 million elderly people are currently affected by Parkinson\xe2\x80\x99s disease in Greater China, creating a significant disease burden.
Located in the major life sciences hubs of Shanghai and Philadelphia, SciNeuro is establishing a robust CNS product pipeline through internal innovation and global partnerships.

Groundbreaking research award established to discover an accurate method of diagnosing Lewy body dementia

Retrieved on:

Thursday, April 15, 2021

Cognitive disorders, Lewy body dementia, Psychiatric diagnosis, Branches of biology, Psychiatry, Dementia, Aging-associated diseases, Clinical medicine, Lewy body, Lewy, Dementia with Lewy bodies, Dementia with Lewy Bodies Consortium

Fox Foundation for Parkinson\'s Research and the American Academy of Neurology to establish its 2022 Cure One, Cure Many Award: A research award for early diagnosis of Lewy body dementia.

Key Points:

Fox Foundation for Parkinson\'s Research and the American Academy of Neurology to establish its 2022 Cure One, Cure Many Award: A research award for early diagnosis of Lewy body dementia.
The hope is that this will lead to an accurate method of diagnosing the disease giving patients and their loved ones clarity about the prognosis.
"Shared pathology across Parkinson\'s disease and Lewy body dementia means that better understanding the biology of one can help advance research into the other, growing the impact of this program across diagnostic lines.
To learn more about the award and to see how you can help support this initiative, visit americanbrainfoundation.org/cocm\n'

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies

Retrieved on:

Tuesday, April 6, 2021

Modulation of NMDA glutamate receptors to address this underlying disease pathology is a compelling approach to treating the broad spectrum of symptoms associated with cognitive impairment.

Key Points:

Modulation of NMDA glutamate receptors to address this underlying disease pathology is a compelling approach to treating the broad spectrum of symptoms associated with cognitive impairment.
The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study to evaluate the safety and potential cognitive benefits of NYX-458 in approximately 100 patients with mild cognitive impairment or mild dementia associated with Parkinsons disease or prodromal or manifest dementia with Lewy bodies.
Cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies is characterized by a broad range of deficits related to attention, memory, and executive function.
NYX-458 is a novel oral NMDA receptor modulator currently in clinical development for the treatment of cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies.

AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline

Retrieved on:

Friday, March 26, 2021

Branches of biology, Alpha-synuclein, Lewy body dementia, Tau protein, Brachyury, Biology

During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Companys innovative Morphomer technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins.

Key Points:

During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Companys innovative Morphomer technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins.
The platform has produced multiple clinically validated therapeutic and diagnostic candidates that bind selectively to target proteins intracellularly, at the earliest stages of disease.
The current Morphomer pipeline includes two clinical-stage diagnostic candidates (Tau-PET tracer and alpha-synuclein-PET tracer), and one therapeutic candidate that has completed Phase 1 (Morphomer Tau ACI-3024).
Following the formal presentations, there will be an interactive virtual roundtable discussion between the audience and the AC Immune Management and Research and Development Teams.

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference

Retrieved on:

Monday, February 22, 2021

Branches of biology, Peripheral membrane proteins, Lewy body dementia, Neurodegenerative disorders, Psychiatric diagnosis, Alpha-synuclein, Parkinson's disease, Synuclein

These outcomes suggest a mechanistic understanding of the role of alpha-synuclein plaques in the onset of disease.

Key Points:

These outcomes suggest a mechanistic understanding of the role of alpha-synuclein plaques in the onset of disease.
Details for the presentation are below:
Following the presentation, there will be a live panel discussion and Q&A session from 11:00-11:15am ET.
"We are excited to share some of the preclinical results of our IkT-148009 program at the ASENT 2021 conference.
Inhibikase (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.